Release Date: December 13, 2019
Valid for Credit Through: December 31, 2020
Target Audience
This activity is designed to meet the educational needs of physicians, nurses and nurse midwives, advanced practice clinicians, and pharmacists, who manage patients with multiple sclerosis (MS).
Program Description
Multiple sclerosis (MS) has a female predominance of approximately 3 to 1 and appears to be increasing among young women who are of reproductive age at the time of diagnosis. The impact of the disease and its treatment on the health of a pregnant mother and the developing fetus is a critical issue. While it may seem prudent to recommend that women discontinue disease-modifying therapy (DMT) before pregnancy or if a pregnancy is confirmed, this decision must be made on a case-by-case basis. Healthcare professionals require the latest information about DMT use during pregnancy, including available data on approved therapies and labeling recommendations that may influence this decision-making process.
Commercial Support Acknowledgement
This webinar is supported by an educational grant from Bayer HealthCare Pharmaceuticals
Faculty
Patricia K. Coyle, MD
Professor of Neurology
Director, MS Comprehensive Care Center
Stony Brook Neurosciences Institute
Stony Brook, NY
Patricia Melville, NP
Nurse Practitioner
Stony Brook Neurosciences Institute
Stony Brook, NY
Disclosure Statements
Patricia Coyle, MD has disclosed the following financial relationships: Consulting Fees: Accordant, Alexion, Bayer, Biogen, Celgene, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Mylan, Novartis, Serono, and TG Therapeutics; and Contracted Research: Actelion, Alkermes, Corrona LLD, Genentech/Roche, MedDay, NINDS, Novartis, and PCORI.
Patricia Melville, NP has disclosed the following financial relationships: Consulting Fees: Sanofi-Genzyme; and Speakers Bureau: Biogen, Sanofi-Genzyme, Novartis, and EMD Serono.
June Halper, MSN, APN-C, MSCN, FAAN served as Planner for this activity and has disclosed no relevant financial relationships.
The following planners and managers have disclosed no relevant financial relationships: Joseph J. D’Onofrio, Frank Marino, Katherine Wandersee.
Learning Objectives
1) Assess factors informing the continuation or discontinuation of disease-modifying therapy (DMT) for patients with MS who are pregnant or planning pregnancy.
2) Evaluate treatment of MS for patients who require ongoing DMT during all or part of pregnancy.
3) Analyze data and discuss outcomes from registries and databases of women exposed to various DMT agents during pregnancy.
4) Discuss counseling strategies for women with MS and their partners to best control MS while optimizing a safe, healthy pregnancy.
Accreditation Statement and Credit Designations
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Delaware Media Group. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The CMSC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
The CMSC designates this enduring material for 1.0 continuing education nursing credit (1.0 in the area of pharmacology).
Pharmacists
The Consortium of Multiple Sclerosis Centers (CMSC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education and will award 1.0 contact hours (.1 CEUs) to pharmacists who (1) participant in the activity, (2) pass the post-test, and (3) complete the evaluation form. The Universal Activity Number (UAN) for this activity is JA4008165-9999-19-011-H01-P. This is a knowledge-based activity.
Upon successful completion of the activity, your CE credits will be submitted electronically to the NABP CPE Monitor service. For information about CPE Monitor, visit https://nabp.pharmacy/cpe-monitor-service/
PAs
The CMSC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.
The CMSC designates this enduring material for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Certificate of Participation for Other Healthcare Professionals
A Certificate of Participation will be given upon completion of the activity enabling participants to register their credit with the appropriate licensing boards or associations.
Method of Participation
Follow these steps to earn CE credit:
1. Read the target audience, learning objectives, and author disclosures.
2. Study the educational content online
3. Complete the post test and evaluation.
Statements of Credit are awarded upon successful completion of the post-test with a passing score of >75% and the evaluation.
Release Date: December 13, 2019
Valid for Credit Through: December 31, 2020
There is no fee to participate in this activity.
How to Claim Credit
1. To complete the evaluation, post-test, and claim credit, please click on the To Claim Credit button below or go to: highmarksce.com/mscare/.
2. Log in with your user name and password*, or create a new account.
3. Select the Enduring Materials tab, then select this activity from the listing and follow the instructions to complete the activity and receive your credit.
*If you forgot your username or password, click on Forgot password. You will receive an email with a link to change your password.
Disclosure of Unlabeled use
This CE activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. CMSC, Delaware Media Group, and the supporters do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of CMSC, Delaware Media Group, or the supporters.
Privacy Policy
Copyright© 2019, Delaware Media Group, Inc. All rights reserved. None of the contents of this webinar program may be reproduced in any form without prior written permission. The opinions expressed in this program are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, or the supporters.
If you have any questions about this CE activity, please contact the CMSC at [email protected] or 201-487-1050.